Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 1 mg) |
Drug Class | Alkylating agents |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Trabectedin (Yondelis) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen. It offers comparable therapeutic efficacy to pazopanib in treating previously treated metastatic synovial sarcoma, with marginal differences in survival outcomes.
- The information was derived from two studies that focused on trabectedin's effectiveness and safety profile compared to another agent, pazopanib.
- In terms of overall survival rates and response rate, there were negligible differences between treatments involving trabectedin and pazopanib. However, a slightly better performance by pazopanib was observed in the overall response rate.
- A crucial safety concern associated with trabectedin therapy is cardiac toxicity. An estimated incidence of cardiac toxicity at 3.4% has been reported, indicating an increase in heart failure cases linked to this drug than previously acknowledged.
- Patients who have had previous exposure to anthracyclines are potentially at elevated risk for developing trabectedin-induced heart failure; hence, meticulous patient selection and monitoring are essential, especially for those with a history of anthracycline treatment.
- Proactive measures such as the implementation of NT-pro-BNP assays have been suggested for early detection and intervention against the potential development of heart failures related to the use of trabectedin (Yondelis).
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Yondelis (trabectedin) Prescribing Information. | 2020 | Baxter Oncology GmbH, Halle/Westfalen, Germany |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). | 2022 | Future Oncology |
Trabectedin-related heart failure: case report and a systematic review of the literature. | 2021 | Frontiers in Oncology |